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Abstract 
Aristolochic acid I (AAI) is the major toxic component of the plant extract aristolochic acid, 
which leads to the development of nephropathy and urothelial cancer in human. Individual 
susceptibility to AAI-induced disease might reflect variability in enzymes that metabolize 
AAI. In vitro NAD(P)H:quinone oxidoreductase (NQO1) is the most potent enzyme that 
activates AAI by catalyzing formation of AAI-DNA adducts which are found in kidneys of 
patients exposed to AAI. Inhibition of renal NQO1 activity by dicoumarol has been shown in 
mice. Here we studied the influence of dicoumarol on metabolic activation of AAI in Wistar 
rats in vivo. In contrast to previous in vitro findings dicoumarol did not inhibit AAI-DNA 
adduct formation in rats. Compared with rats treated with AAI alone, 11- and 5.4- fold higher 
AAI-DNA adduct levels were detected in liver and kidney, respectively, of rats pretreated 
with dicoumarol prior to exposure to AAI. Cytosols and microsomes isolated from liver and 
kidney of these rats were analyzed for activity and protein levels of enzymes known to be 
involved in AAI metabolism. The combination of dicoumarol with AAI induced NQO1 
protein level and activity in both organs. This was paralleled by an increase in AAI-DNA 
adduct levels found in ex vivo incubations with cytosols from rats pretreated with dicoumarol 
compared to cytosols from untreated rats. Microsomal ex vivo incubations showed a lower 
AAI detoxication to its oxidative metabolite, 8-hydroxyaristolochic acid (AAIa), although 
cytochrome P450 (CYP) 1A was practically unchanged. Because of these unexpected results 
we examined CYP2C activity in microsomes and found that treatment of rats with dicoumarol 
alone and in combination with AAI inhibited CYP2C6/11 in liver. Therefore these results 
indicate that CYP2C enzymes might contribute to AAI detoxication.  
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Introduction 
The herbal drug aristolochic acid (AA) derived from Aristolochia species is considered to be 
the cause of aristolochic acid nephropathy (AAN) (1-4), which is a rapidly progressive renal 
fibrosis, with a high risk for the patients of developing upper urothelial tract carcinoma and, 
subsequently, bladder urothelial carcinoma (4-5). Exposure to AA has also been linked to 
inhabitants of rural areas in the Balkans who develop nephropathy − Balkan endemic 
nephropathy (BEN) (4,7-9). Exposure of experimental animals to AA leads to characteristic 
AA-DNA adducts in renal tissue after reductive activation. The same DNA adducts, mainly 7-
(deoxyadenosin-N6-yl)aristolactam I (dA-AAI) (Fig. 1), were detected in kidneys of AAN and 
BEN patients whereby their exposure to AA was identified (5,6,8,10-12). This 
deoxyadenosine adduct causes characteristic AT→TA transversions in critical genes of 
oncogenesis (e.g. TP53 tumor suppressor gene) and such AT→TA mutations have indeed 
been found in urothelial tumors in AA-exposed humans (8,9.13-16), indicating a molecular 
mechanism associated with AA-induced carcinogenesis (7,17). AA has been classified as a 
Group I carcinogen by the International Agency for Research on Cancer.  
AAI is activated by nitroreduction by both cytosolic and microsomal enzymes. Of the 
enzymes characterized so far, cytosolic NAD(P)H:quinone oxidoreductase (NQO1) was 
found to be the most active enzyme both in experimental animals and in human tissue (18-22) 
(Fig. 1). In microsomes from human liver, cytochrome P450 (CYP) 1A2 is the most active 
reductase followed by CYP1A1 and NADPH:CYP reductase (POR) (23-26). However, the 
two isoenzymes of the CYP1A family are mainly responsible for the oxidative demethylation 
of AAI to 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa; Fig. 1) (24-27).  
Previous studies with genetically engineered mice such as Hepatic P450 Reductase Null 
(HRN) mice which lack hepatic POR and therefore essentially all CYP-activity in 
hepatocytes, with Cyp1a1(−/−), Cyp1a2(−/−) and Cyp1a1/1a2(−/−) knockouts as well as with 
CYP1A-humanized mice demonstrated that the balance between reductive activation and 
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oxidative detoxication of AAI depends on the expression of both CYP1A1/1A2 and NQO1 
(24-26,28). The knockout of enzymes which mainly detoxicate AAI was not the only reason 
for the observed higher DNA adduct levels, but a concomitant 3-fold increase in NQO1 
protein levels in the livers of these mice was also important (26). Cytosolic fractions isolated 
from HRN mice activated AAI more efficiently to DNA adducts than hepatic cytosols of WT 
mice. These findings emphasized the importance of NQO1 not only for the activation of AAI 
in vitro, but also in vivo. AAI was also found to induce NQO1 protein levels and its enzyme 
activity in liver, kidney and lung of mice (26,28,29) and of Wistar rats treated with this 
compound (19). Again, higher NQO1 enzyme activity was associated with increased AAI-
DNA adduct formation in ex vivo incubations of cytosols with AAI and DNA (26,28). Hence, 
AAI induces NQO1 and thereby its own metabolic activation leading to increased 
genotoxicity in vivo. 
A role of NQO1 in renal AAI nitroreduction in vivo was proven in mice (male C57BL/6 
mice) (22) in which the modulation of AAI metabolism by dicoumarol, an inhibitor of NQO1, 
was investigated. NQO1 activity was inhibited in dicoumarol-pretreated mice resulting in 
decreased levels of the reductive metabolite aristolactam I in kidney and increased amounts of 
AAI as well as AAIa in serum of AAI-exposed mice. 
In the present study we investigated whether dicoumarol influences the genotoxicity of 
AAI in rats in vivo. In addition, the effect of this NQO1 inhibitor alone or in combination with 
AAI on enzymes metabolizing AAI (NQO1, CYP1A1/2) was investigated. DNA adduct 
formation by AAI was evaluated by the 32P-postlabeling method in vivo and in ex vivo 
incubations using cytosols and microsomes isolated from kidneys and livers. Further, the AAI 
metabolite AAIa in these ex vivo incubations was measured by high pressure liquid 
chromatography (HPLC).  
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Materials and methods 
Chemicals  
NADPH, AAI (sodium salt), dicoumarol, Sudan I [1-(phenylazo)-2-hydroxynaphthalene], 
menadione (2-methyl-1,4-naphthoquinone) and calf thymus DNA were from Sigma Chemical 
Co (St Louis, MO, USA). 7-ethoxyresorufin and 7-methoxyresorufin were from Fluka 
Chemie AG (Buchs, Switzerland). Enzymes and chemicals for the 32P-postlabeling assay 
were from sources described (23).  
 
Animal experiments and sample preparation 
The study was conducted in accordance with the Regulations for the Care and Use of 
Laboratory Animals (311/1997, Ministry of Agriculture, Czech Republic), which is in 
compliance with the Declaration of Helsinki. Animals were acclimatized for 5 days and 
maintained at 22°C with a 12 h light/dark period. Standardized diet and water were provided 
ad libitum. Groups of five weeks old male Wistar rats (∼150 g, n = 3/group) were treated with 
dicoumarol, dissolved in sunflower oil. Dicoumarol was administered by gavage to rats twice 
at either 30 or 60 mg/kg body weight (bw), once at 3 p.m. and again the next day at 8 a.m. 
(total doses were 60 or 120 mg dicoumarol/kg bw). Another group of rats was injected i.p. 
with a single dose of AAI dissolved in 1% NaHCO3 (20 mg/kg bw). In the study on the effect 
of dicoumarol on AAI-mediated DNA adduct formation, a dose of 20 mg/kg bw of AAI was 
given by a single i.p. injection 2.5 h after the second dose of dicoumarol. Animals were killed 
24 h after AAI treatment. Animals in the control groups received the vehicle only. Livers and 
kidneys were removed after sacrifice, frozen in liquid nitrogen and stored at −80oC until 
analysis. DNA from livers and kidneys was isolated by extraction with phenol/chloroform 
(10). Microsomes and cytosols were isolated from the rat tissues by the procedure described 
previously (18,23). Protein concentration in the microsomal fraction was measured using 
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bicinchoninic acid protein assay (30) with bovine serum albumin as a standard. Pooled 
microsomal and cytosolic samples (n = 3 rats/group) were used for the analyses.  
 
DNA adduct analysis by 32P-postlabeling  
The nuclease P1 enrichment version of 32P-postlabeling analysis, and thin-layer 
chromatography (TLC) on polyethylenimine-cellulose (PEI) plates were carried out and DNA 
adduct levels (RAL, relative adduct labeling) were calculated as described previously (10,31). 
AA-DNA adducts were identified using reference standards as described (10).  
 
Preparation of antibodies and estimation of CYP1A1, 1A2, and NQO1 protein content in 
microsomal and cytosolic fractions isolated from rat liver and kidney 
The chicken anti-rat CYP1A1, anti-rabbit CYP1A2 and anti-rat NQO1 antibodies were 
prepared as described previously (32,33). Immunoquantification of microsomal CYP1A1 and 
1A2 and cytosolic NQO1 was performed using Western blotting (33). Rat CYP1A1, rabbit 
CYP1A2 and human NQO1 (Sigma) were used to identify the CYP1A1, 1A2 and NQO1 bands, 
respectively. The antigen-antibody complex was visualized with an alkaline phosphatase-
conjugated rabbit anti-chicken IgG antibody and 5-bromo-4-chloro-3-
indolylphosphate/nitroblue tetrazolium as dye and bands are expressed as arbitrary units 
(AU)/mg protein (32,33). Glyceraldehyde phosphate dehydrogenase was used as loading 
control and detected by its antibody (1:750, Millipore; MA, USA). 
 
NQO1, CYP1A1/2 and 2C6/11 enzyme activity assays 
In hepatic and renal cytosols NQO1 activity was measured using menadione (2-methyl-1,4-
naphthoquinone) as a substrate; the assay was improved by the addition of cytochrome c and 
NQO1 activity expressed as nmol cytochrome c reduced  (26,28). Microsomal samples were 
characterized for specific CYP1A1 and 1A2 activities: ethoxyresorufin O-deethylation 
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(EROD) (CYP1A1/2) and methoxyresorufin O-demethylation (MROD) (CYP1A2) (34). 
CYP1A1 enzyme activity was also monitored by Sudan I hydroxylation to 4’-hydroxy-, 6-
hydroxy-, and 4’,6-dihydroxy-Sudan I (22). Hepatic microsomal samples were also 
characterized for specific CYP2C6 and 2C11 activities with their marker substrates 
determining diclofenac 4’-hydroxylation and testosterone 16α-hydroxylation, respectively 
(35,36). In hepatic microsomes POR activity was analyzed using cytochrome c as a substrate 
(24).  
 
Cytosolic and microsomal formation of AAI-DNA adducts 
The  de-aerated and nitrogen-purged incubation mixtures, in which cytosols were used to 
activate AAI contained 50 mM Tris-HCl buffer (pH 7.4), 0.2% Tween 20, 1 mM NADPH, 1 
mg rat hepatic or renal cytosolic protein, 0.5 mg calf thymus DNA (2 mM dNp) and 0.5 mM 
AAI in a final volume of 750 µl. Incubations with cytosols were performed at 37°C for 60 
min; AAI-derived DNA adduct formation was found to be linear up to 2 h (18). Control 
incubations were performed either (i) without cytosol, (ii) without NADPH, (iii) without 
DNA or (iv) without AAI. After extraction with ethyl acetate DNA was isolated from the 
residual water phase by the phenol/chloroform extraction method as described (20,23,25). 
The de-aerated and nitrogen-purged incubation mixtures, in which microsomes were used 
to activate AAI contained 50 mM potassium phosphate buffer (pH 7.4), 1 mM NADPH, 1 mg 
of hepatic or renal microsomal protein, 0.5 mg of calf thymus DNA (2 mM dNp) and 0.5 mM 
AAI in a final volume of 750 µl. Microsomal incubations were carried out at 37°C for 60 min; 
AAI-DNA adduct formation was found to be linear up to 2 h in microsomes (23). Control 
incubations were carried out either (i) without microsomes, (ii) without NADPH, (iii) without 
DNA or (iv) without AAI. After extraction with ethyl acetate, DNA was isolated from the 
residual water phase as described above.  
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Microsomal incubations to study AAI demethylation 
Incubation mixtures contained 100 mM potassium phosphate buffer (pH 7.4), 1 mM NADPH, 
1 mg rat hepatic or renal microsomal protein and 10 µM AAI in a final volume of 250 µl and 
were incubated at 37°C for 20 min; AAI O-demethylation to AAIa was determined to be 
linear up to 25 min. Control incubations were carried out either (i) without microsomes, (ii) 
without NADPH or (iii) without AAI. AAI and its metabolite AAIa were separated by 
reverse-phase HPLC, identified by mass spectrometry and quantified as described previously 
(26). Briefly, HPLC was carried our with an Nucleosil 100-5 C18, 25 × 4.0 mm, 5 mm 
(Macherey-Nagel) column, using a linear gradient of acetonitrile (20-60% acetonitrile in 55 
min) in 100 mM triethylamonium acetate with a flow rate of 0.6 ml/min. A Dionex HPLC 
pump P580 with UV/VIS UVD 170S/340S spectrophotometer detector set at 254 nm were 
used. Peaks were integrated with CHROMELEON™ 6.01 integrator. A peak eluting at 
retention time (r.t.) 22.7 min was identified as AAIa using mass-spectroscopy analysis (26). A 
typical HPLC chromatogram is shown as a supplementary Figure 1. 
 
Statistical Analyses 
For statistical data analysis we used Student’s t-test. All P-values are two-tailed and 
considered significant at the 0.05 level.  
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Results 
DNA adduct formation in rats treated with dicoumarol and AAI compared to adduct 
formation in rats treated with AAI alone 
AAI-DNA adduct formation was determined by 32P-postlabeling in liver and kidney of rats 
treated with a single i.p. dose of 20 mg/kg bw of AAI. Similarly, rats pretreated orally with 
total doses of 60 and of 120 mg/kg bw of the NQO1 inhibitor dicoumarol prior to AAI 
injection were analysed. AAI-DNA adduct patterns in both organs were similar to those found 
in vivo in humans and consisted of two major adducts (spots 1 and 2) and one minor adduct 
(spot 3) (see Fig. 2, insert) (1,5,10,13). These adducts have been identified to be 7-
(deoxyadenosin-N6-yl)aristolactam I (dA-AAI; spot 1), 7-(deoxyguanosin-N2-yl)aristolactam I 
(dG-AAI; spot 2) and 7-(deoxyadenosin-N6-yl)aristolactam II (dA-AAII; spot 3). No adducts 
were found in DNA of control rats treated with vehicle only or in those treated with 
dicoumarol alone (data not shown).  
In all rats the levels of AAI-DNA adducts were higher in liver than in kidney, the target 
organ of AAI genotoxicity (Fig. 2). Interestingly, in contrast to the strong inhibition by 
dicoumarol observed in vitro (18,26), the opposite effect upon AAI-DNA adduct formation 
was found in vivo. In both organs analyzed AAI-DNA adduct levels increased with the 
dicoumarol dose used in the pretreatment. Compared to adduct levels found in rats treated 
with AAI alone, DNA binding was 11- and 5.4-fold higher in liver and kidney, respectively, 
of rats pretreated with a total dose of 120 mg/kg bw of dicoumarol prior to exposure to AAI 
(P<0.001). Therefore, dicoumarol, when administered to rats prior to AAI, seems to induce 
pathways activating AAI in both organs. Since NQO1 and CYP1A1/2 might determine the 
AAI-DNA adduct levels their protein levels and enzyme activities were investigated in the 
two rat organs. 
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The effect of dicoumarol treatment with or without AAI upon NQO1 and CYP1A1/2 protein 
levels and their enzymatic activities in rat liver and kidney 
Treatment of rats with AAI led to a significant NQO1 protein induction in kidney cytosol 
(1.4-fold, p<0.05), but not in liver. Likewise, a significantly higher NQO1 enzyme activity 
was found only in kidney of AAI-treated rats (1.5-fold, p<0.001). Whereas administration of 
dicoumarol to rats decreased or did not change NQO1 protein levels in liver, levels increased 
in a dose-dependent manner in kidney. However, treatment of rats with AAI after 
pretreatment with dicoumarol resulted in increased NQO1 protein levels in both organs. 
NQO1 activities in liver cytosols were only significantly higher at the high dicoumarol dose 
in combination with AAI, whereas they were significantly higher in kidney cytosols from rats 
treated with AAI, dicoumarol alone or dicoumarol with AAI (Fig. 3). 
The effect of exposure to AAI and dicoumarol on the protein levels of microsomal 
CYP1A1/2 in rats was also examined as both CYP enzymes play a dual role in AAI 
metabolism. In control rats higher protein levels of CYP1A1 were found in hepatic than in 
renal microsomes by Western blotting (Fig. 4A,B). These levels corresponded with the 
CYP1A enzyme marker activities; EROD for CYP1A1/2 (Fig. 5 C,D) and Sudan I oxidation 
for CYP1A1 (Fig. 5 G,H). As shown in Figures 4 and 5 dicoumarol treatment alone, and 
particularly in combination with AAI, resulted in lower hepatic CYP1A1 protein levels but 
this was not reflected in decreased enzyme activity (i.e. EROD and Sudan I oxidation). In 
contrast, statistically significant ~3-fold higher CYP1A1 protein levels were found in kidneys 
of rats treated with dicoumarol relative to control rats. This was paralleled by Sudan I 
oxidation and this difference was even more pronounced when measuring EROD activities 
(Figs. 4 and 5). AAI also induced renal CYP1A1 protein levels and activities which was 
further enhanced in combination with the lower dicoumarol dose, but did not reach the levels 
induced by dicoumarol alone (Figs. 4 and 5). 
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CYP1A2 was found to be expressed only in rat liver, and not in kidney (Fig. 4D) 
confirming earlier studies showing that CYP1A2 is an almost exclusively hepatic enzyme 
(37). In concordance, MROD activity, a marker reaction of CYP1A2, was found in liver, but 
was negligible in kidney (Fig. 5E,F). AAI and dicoumarol treatment alone as well as 
dicoumarol pretreatment prior to AAI administration resulted in elevated CYP1A2 protein 
levels and MROD activities in the liver (Figs. 4C and 5E), except in the rats treated with  120 
mg/kg bw of dicoumarol prior to AAI administration; CYP1A2 protein level remained while 
MROD activity increased 2-fold. This suggests that the weak CYP1A2 signals detected by 
Western blotting probably do not truly reflect protein levels and determination of enzyme 
activity provides a more accurate assessment of enzyme induction. 
The activity of POR was increased in rat kidney by AAI or dicoumarol treatment alone as 
well as in combined administration, but remained essentially unchanged in liver (Fig. 6). POR 
not only acts as an electron donor in catalytic functions of CYPs (38,39), but is also able to 
activate AAI to some extent (23).  
 
Cytosolic versus microsomal activation of AAI 
In further experiments AAI-DNA adduct formation catalyzed by cytosols isolated from liver 
and kidney of rats from all treatment groups was investigated ex vivo. Cytosols were 
incubated with AAI, DNA and the cofactor of NQO1, NADPH, and analyzed for DNA adduct 
formation by 32P-postlabeling. AAI was activated by the cytosols from both organs as 
evidenced by AAI-DNA adduct formation (Fig. 7 A, B) and the DNA adduct pattern was the 
same as those found in vivo (see Fig. 2, insert). No adducts were observed in control 
incubations carried out in parallel (data not shown). In kidney cytosols from all modes of 
treatment AAI-DNA adduct levels increased up to 3.3-fold relative to cytosols isolated from 
untreated animals (controls). Renal cytosols isolated from AAI-treated rats led to 2.5-fold 
higher adduct levels than cytosol from control animals (p<0.001) (Fig. 7B) and corresponded 
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to higher NQO1 protein levels in these cytosolic samples (compare Figs. 3 and 7). Despite a 
lack of significant NQO1 induction at either protein or activity levels by AAI, DNA adduct 
levels catalyzed by rat hepatic cytosols were 1.7-fold higher than in controls (Fig 3). These 
results indicate that other cytosolic nitroreductases may contribute to the increased AAI-DNA 
adduct formation observed in rat liver cytosol. In this context it is noteworthy that previous 
studies have shown that xanthine oxidase is capable of activating AAI (18,19).  
Consistent with the lower NQO1 protein and activity levels elicited by dicoumarol in 
liver (see Fig. 3A and C), AAI-DNA adduct formation was lower in hepatic cytosol isolated 
from rats treated with 60 mg/kg bw of dicoumarol. However, when rats were treated with 
dicoumarol prior to AAI administration, AAI-DNA adduct levels increased up to 2.6-fold 
relative to hepatic cytosolic incubations from control rats (Fig. 7A). In kidney cytosols from 
all modes of treatment AAI-DNA adduct formation was up to 3.3-fold higher relative to 
controls. 
Because microsomal CYP1A1/2 are also able to activate AAI by nitroreduction to species 
forming DNA adducts, hepatic and renal microsomes of control and treated rats were 
analyzed for their capacity to form AAI-DNA adducts in ex vivo incubations. AAI was 
reductively activated by hepatic and renal microsomes from all rats (Fig. 7C,D). The DNA 
adduct pattern generated was the same as that found in vivo (see Fig. 2, insert). No adducts 
were observed in control incubations carried out in parallel (data not shown). The only 
significant increase in AAI-DNA adduct levels catalyzed by hepatic microsomes was seen in 
the two groups exposed to 60 mg/kg bw dicoumarol (Fig. 7C). AAI-DNA adduct formation 
was up to 2.7-fold higher in kidney microsomes from all treatment groups relative to controls; 
except by those isolated from rats pretreated with 120 mg/kg bw dicoumarol prior to AAI 
administration (Fig. 7D). The reason for such a finding remains to be explained. 
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The effect of treatment of rats with AAI and dicoumarol as well as pretreatment with 
dicoumarol prior to AAI administration on oxidation of AAI to AAIa by rat hepatic and renal 
microsomes  
Since microsomal CYP1A1/2 also detoxify AAI to its O-demethylated metabolite AAIa (23-
25,40), AAIa formation by hepatic and renal microsomes was investigated ex vivo. Under the 
conditions used, liver and kidney microsomes oxidized AAI to AAIa (Fig. 5A,B). A dose-
dependent decrease in AAI oxidation to AAIa in hepatic and renal microsomes (up to ~40% 
relative to controls) was caused by treatment of rats with dicoumarol or pretreatment of rats 
with dicoumarol prior to AAI administration. However, this decrease did not correspond to 
CYP1A enzyme activities shown in Figures 5C and 5D. In order to explain this discrepancy, 
we further investigated the effect of dicoumarol on the oxidation of AAI to AAIa catalyzed by 
rat hepatic microsomes. We found that AAIa formation was strongly inhibited by dicoumarol 
(with an IC50 value of 2 µM), but CYP1A enzyme activity as measured by EROD, MROD 
and Sudan I oxidation did not change (data not shown). Collectively these results suggest that 
not only CYP1A1/2, but also other CYPs might contribute to the oxidation of AAI to AAIa in 
rat hepatic microsomes and that these enzymes are modified by dicoumarol. We hypothesized 
that CYPs of the 2C subfamily might be candidates as they can also oxidize AAI to AAIa to 
some extent (26) and because CYP2C enzymes are highly expressed in the livers of male rats 
accounting for approximately 55% of the rat liver CYP complement (41). Among them 
CYP2C11 and 2C6 contribute about 50% and 20% to the total hepatic CYP2C content in rats, 
respectively (42,43), and both CYP2C isoenzymes have previously been shown to be able to 
O-demethylate AAI to AAIa (26). To test this hypothesis the effect of dicoumarol treatment 
in vivo upon CYP2C6 and 2C11 activities in hepatic microsomes was analyzed (Fig. 8); 
diclofenac 4’-hydroxylation and testosterone 16α-hydroxylation were used as marker 
activities for CYP2C6 and 2C11, respectively (35,36). As shown in Figure 8 exposure of rats 
to dicoumarol, either with or without AAI, decreased testosterone 16α-hydroxylation 
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activities up to 60% relative to control; diclofenac 4’-hydroxylation was reduced up to 20%. 
Therefore, the lower CYP2C enzyme activities could explain the lower oxidation rates of AAI 
to AAIa in these microsomes and indicate that CYP2C11 and 2C6 can contribute to AAIa 
formation in rat liver. 
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Discussion 
Previously we have demonstrated that NQO1 expressed in human, rat or mouse liver and 
kidney as well as purified human and rat NQO1 is the predominant enzyme responsible for 
the genotoxicity of AAI in vitro (18-21). In addition, other studies suggested that NQO1 
might also contribute to AAI-DNA adduct formation in vivo (19-21,24,26,28). In the present 
study we utilized dicoumarol, an inhibitor of NQO1, in a Wistar rat animal model and showed 
that the contribution of NQO1 to AAI activation is complex when comparing in vitro and in 
vivo findings. Bioavailability of AAI to different organs, species differences, length of 
exposure to dicoumarol and AAI, and the applied doses seem to be crucial parameters in the 
effect of this NQO1 inhibitor upon AAI genotoxicity.  
Dicoumarol had previously been administered to male C57BL/6 mice to investigate the 
participation of NQO1 in AAI metabolism and AAI-induced nephrotoxicity (22). The authors 
found that NQO1 indeed plays a crucial role in (renal) AAI nitro-reduction in vivo. They 
showed that NQO1 activity was inhibited in a concentration-dependent manner in mice 
treated with increasing doses of dicoumarol. A single i.p. injection of AAI 2.5 h after 
dicoumarol pretreatment resulted in decreased levels of its reductive metabolite aristolactam I 
in kidney. As a consequence levels of AAI, and particularly AAIa, in serum and kidney were 
higher in dicoumarol-pretreated mice. Furthermore, pretreatment with this NQO1 inhibitor 
decreased AAI-induced nephrotoxicity and increased the survival rate of these mice (22). 
Collectively, these results suggested that dicoumarol acts as an inhibitor of AAI reduction in 
this mouse model.  
 The aim of the present study was to evaluate the formation of AAI-DNA adducts in rats 
exposed to AAI in the presence of two concentrations of dicoumarol. We administered the 
higher doses of dicoumarol and AAI and the same dosing schedule as Chen et al. (22) that 
had been used for mice, and AAI-DNA adduct formation was monitored as the biological 
end-point of AAI genotoxicity. The resultant adduct levels obtained in vivo and in ex vivo 
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incubations were used as a surrogate measure of the activity of enzymes involved in AAI 
bioactivation. Previous studies in rats have shown that dicoumarol is still present up to 10 h 
after oral administration and concentrations probably increasing in blood due to the slow 
uptake from the intestine (44). In addition dicoumarol has a long elimination half-live ranging 
from 5-25 h in rats (45). Here we found that AAI-DNA adduct levels in kidney, and 
particularly in liver, were higher in rats treated with dicoumarol prior to AAI administration 
(Figs. 2 and 9). This finding is unexpected since NQO1, the target of dicoumarol inhibition, is 
the primary AAI activating enzyme in rats, mice and humans.  
Hepatic cytosols from rats treated with dicoumarol showed the same NQO1 protein 
levels as those from untreated rats, whereas the enzyme activities were decreased ~2-fold. 
This may be due to dicoumarol still binding to NQO1 as dicoumarol has strong protein 
binding properties. It is expected that due to its long elimination half-life from blood residual 
dicoumarol may remain in tissues, particularly in liver as its main site of metabolism (45). 
The decreased NQO1 enzyme activity resulted in lower DNA adduct formation in ex vivo 
incubation with AAI using hepatic cytosols. The situation in the kidney was more complex. 
Because the effect of residual dicoumarol upon enzyme activity ex vivo was not observed, 
overall dicoumarol concentrations might be lower in the kidney compared to liver (45). In 
kidney dicoumarol induced NQO1 protein levels and also activity. Furthermore, in liver and 
kidney NQO1 protein levels and activity was induced by treating rats with dicoumarol prior to 
AAI administration and this corresponded to higher levels of AAI-DNA adducts formed in 
vivo and in ex vivo incubations of AAI with cytosols of these organs. 
Higher adduct levels found in liver and kidney of rats pretreated with dicoumarol prior 
to AAI administration might be, beside increased levels and activities of NQO1, also the 
result of higher protein levels and activities of CYP1A1 in kidney and CYP1A2 in liver. 
Namely, the two CYP1A enzymes can reductively activate AAI to DNA binding (24-26). 
However, an increase in the levels of AAI-DNA adducts formed in ex vivo incubations of 
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AAI with hepatic and renal microsomes from rats treated with dicoumarol prior to AAI was 
lower than that generated in ex vivo incubations of AAI with cytosols from these rats (see Fig. 
7). The reductive activation of AAI by these two CYP1A enzymes might therefore be less 
important for an increase in AAI-DNA adduct levels in rat liver and kidney in vivo than 
induction of NQO1. Furthermore, oxidation of AAI by both CYPs was found to lead to AAIa 
formation (Fig. 1) (24-26). In the present study the detoxication metabolite AAIa generated in 
ex vivo incubations was lower in microsomes isolated from either kidney or liver from rats 
treated with dicoumarol relative to controls. Here again as in the case of NQO1 we expect 
dicoumarol to still be present in hepatic microsomes (45). The low IC50 value of 2 µM 
dicoumarol determined for the inhibition of AAIa formation in hepatic microsomes shows 
that only small amounts of dicoumarol need to be bound to affect AAI demethylation. This is 
in strong contrast to the observation of increased AAIa serum levels in dicoumarol-pretreated 
mice administered AAI (22). This would point to another enzyme system or another organ 
demethylating AAI in vivo, at least in mice. Since dicoumarol inhibition of AAIa formation in 
hepatic microsomes did not correlate with CYP1A1/2 activity, other CYPs were considered. 
We examined the specific activities of two members of the rat CYP2C subfamily also known 
to O-demethylate AAI to AAIa (26). Indeed both CYP2C11 and 2C6 enzyme activities were 
inhibited by dicoumarol; the same effect was also seen in combination with AAI treatment. 
Dicoumarol itself is mainly metabolized in the liver and earlier work showed that human 
CYP2C is responsible (46), although it is noteworthy that this finding has not been further 
investigated. The authors used antibodies generated against rat CYP2C7 and 2C11 and found 
that formation of 7-hydroxy-dicoumarol in human hepatic microsomes was inhibited by 50-
60% (46). Collectively, these data suggest a competitive inhibition of CYP2C activity by 
residual dicoumarol in our ex vivo system. In addition, an inhibition of O-demethylation of 
AAI to AAIa was even higher when rats were treated with dicoumarol and AAI (see Fig. 5A). 
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All these findings indicate that higher adduct levels found in the liver of rats pretreated 
with dicoumarol prior to AAI administration might be, beside induction of NQO1, also 
caused by decreased AAI detoxication to AAIa due to CYP2C inhibition by dicoumarol and 
AAI. Higher levels of AAI are available for its reductive activation to form AAI-DNA 
adducts (Fig. 9). In kidney induction of NQO1 with dicoumarol and AAI seems to be the 
predominant process responsible for higher levels of AAI-DNA adducts in this organ (Fig. 9). 
The inductive effect of AAI on NQO1 found in this work confirmed previous studies, 
where NQO1 protein levels and its enzyme activity were induced by AAI in kidney of mice 
(26,28,29). Thus, NQO1 might also be induced in the kidneys of patients suffering from AAN 
and BEN, and this feature can contribute to an elevated risk for cancer. However, in this study 
we found for the first time that dicoumarol also induces the NQO1 protein and its enzyme 
activity in the AAI target organ kidney. Because dicoumarol is used in medicine as an 
anticoagulant drug that functions as a vitamin K antagonist (similar to warfarin for which it 
was the inspiration) [reviewed in (47,48)], such an induction might increase AAI-DNA adduct 
formation leading to a higher risk of AAI-mediated development of urothelial cancer in 
humans exposed to AA. 
Even though we demonstrate in the present study that both AAI and dicoumarol 
increased NQO1 protein levels and activity, the mechanism(s) are not yet clear. NQO1 
induction has been widely investigated in a variety of studies [reviewed in (49-53)]. Protein 
levels of NQO1 are induced by several chemicals, often by pathways generating reactive 
oxygen species (ROS). NQO1 gene expression is primarily regulated by the KEAP1/NRF 
(NF-E2-related factor 2) pathway, which controls redox homeostasis and facilitates the 
adaptation of most cells to oxidative stress (50-53.). Because ROS have been found in some 
human cells treated with AAI (54,55), ROS formation caused by AAI might contribute to 
NQO1 induction.  
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NQO1 is known to be implicated in vitamin K metabolism; it is identical to the so-called 
dicoumarol-inhibited vitamin K reductase (53,56). Because vitamin K is redox-cycled during 
its metabolism by other enzymes, ROS might be generated in the one-electron redox reactions 
in this metabolism (53,57). Since NQO1 competes with enzymes that redox cycle vitamin K 
and catalyzes two-electron reduction of vitamin K, less semiquinone and ROS are formed. If 
dicoumarol inhibits NQO1 activity, a significant increase in ROS might occur (53,56) also 
resulting in enhanced NQO1 expression. Because our data in rats and the results of the mouse 
study (22) do not unequivocally answer the question how important NQO1 is for AAI 
activation in vivo, utilization of NQO1-knockout animal models (58) may bring a definite 
proof. The elucidation of the contribution of NQO1 to AAI bioactivation resulting in its 
genototoxicity and nephrotoxicity is of great importance. The activity of NQO1 in humans 
may differ significantly among individuals, because, beside its induciblity, the gene is 
polymorphic. Therefore, the impact of NQO1 genotype on AAI-induced nephropathy and 
urothelial cancer in humans remains still to be clarified. We propose that analyses of the 
expression levels and activities of enzymes metabolizing AAI in AAN and BEN patients may 
clarify to which extent they contribute to the development of AA-induced nephropathies and 
cancer. 
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Legends to Figures 
 
Figure 1.  Pathways of biotransformation and DNA adduct formation of AAI. dA-AAI, 7-
(deoxyadenosin-N6-yl)aristolactam I; dG-AAI, 7-(deoxyguanosin-N2-yl)aristolactam I; 
NR, nitro-reduction; Uridine-diphosphate-β-D-glucuronosyltransferase; SULT, 
sulfotransferase.  
Figure 2. Quantitative TLC 32P-postlabeling analysis of AAI-DNA adduct levels in organs of 
rats treated i.p. with a single dose of 20 mg/kg bw AAI with or without the pretreatment 
with dicoumarol (total doses of 60 [DC60] or 120 mg [DC120] dicoumarol/kg bw) (see 
Materials and Methods for details). Numbers above columns (“F”) indicate fold changes 
in DNA adduct levels in AAI-treated animals pretreated with dicoumarol compared to 
animals treated with AAI alone. Values are given as the means ± SD (n = 3); each DNA 
sample was determined by two postlabeled analyses. RAL, relative adduct labelling. 
Comparison was performed by t-test analysis; *P < 0.05, **P < 0.01, ***P < 0.001, 
different from animals treated with AAI alone. Insert: autoradiographic profile of AA-
DNA adducts in rat liver using the nuclease P1 enrichment version of the assay. The 
adduct profile shown is representative of those obtained in other organs investigated. The 
origin, in the bottom left-hand corner, was cut off before exposure. Spot 1, dA-AAI; spot 
2, dG-AAI; and spot 3, dA-AAII. 
Figure 3. NQO1 enzyme activity (A, B) and NQO1 protein levels (C, D) in rat cytosols 
isolated from untreated (control) animals and animals pretreated orally with dicoumarol 
(total doses of 60 [DC60] or 120 mg [DC120] dicoumarol/kg bw) alone or in combination 
with AAI (single i.p. dose of 20 mg/kg bw). NQO1 activity in hepatic (A) and renal 
cytosols (B) was determined using menadione and cytochrome c as substrate, (expressed 
as nanomoles cytochrome c per minute per milligram protein). Cytosol isolated from liver 
(C), or kidney (D) was analyzed by Western blotting in the same blot (insert) and, 
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therefore, can be compared directly. Human recombinant NQO1 (Sigma) was used to 
identify the rat NQO1 band in rat cytosol (data not shown). Numbers above columns 
(“F”) indicate fold changes in protein level or enzyme activity compared to control. 
Values are given as the means ± SD (n = 3). Comparison was performed by t-test 
analysis; *P < 0.05, **P < 0.01, ***P < 0.001, different from control.  
Figure 4.  CYP1A1 (A, B) and CYP1A2 (C, D) protein levels in rat microsomes isolated from 
untreated (control) animals and animals pretreated orally with dicoumarol (total doses of 
60 [DC60] or 120 mg [DC120] dicoumarol/kg bw) alone or in combination with AAI 
(single i.p. dose of 20 mg/kg bw). Microsomes isolated from liver (A, C) and kidney (B, 
D) were analyzed by Western blotting in the same blot (insert) and therefore can be 
directly compared. Rat recombinant CYP1A2 was used to identify the rat CYP1A2 band 
(see panel D). Values are given as the means of arbitrary units (AU) ± SD (n = 3). 
Numbers above columns  (“F”) indicate fold changes in protein level or enzyme activity 
compared to control. ND, not detected. Comparison was performed by t-test analysis; *P 
< 0.05, **P < 0.01, ***P < 0.001, different from control.  
Figure 5. AAI oxidation to AAIa and CYP1A enzyme activities in rat microsomes isolated 
from untreated (control) animals and animals pretreated orally with dicoumarol (total 
doses of 60 [DC60] or 120 mg [DC120] dicoumarol/kg bw) alone or in combination with 
AAI (single i.p. dose of 20 mg/kg bw). Formation of AAIa (peak area per minute per 
miligram protein) from AAI in hepatic (A) and renal (B) microsomes. CYP1A enzyme 
activity as measured by EROD activity (picomoles resorufin per minute per milligram 
protein) (C, D), MROD activity (picomoles resorufin per minute per milligram protein) 
(E, F) or Sudan I oxidation (nanomoles total C-hydroxylated metabolites per minute per 
milligram protein) (G, H). All values are given as the means ± SD (n = 3). Numbers 
above columns (“F”) indicate fold changes in AAIa levels or enzyme activities compared 
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to control. ND, not detected. Comparison was performed by t-test analysis; *P < 0.05, 
**P < 0.01, ***P < 0.001, different from control. 
Figure 6. POR enzymatic activity in rat microsomes isolated from untreated (control) animals 
and animals pretreated orally with dicoumarol (total doses of 60 [DC60] or 120 mg 
[DC120] dicoumarol/kg bw) alone or in combination with AAI (single i.p. dose of 20 
mg/kg bw). POR was measured using cytochrome c as substrate (nanomoles cytochrome 
c per minute per milligram protein). All values are given as the means ± SD (n = 3). 
Numbers above columns (“F”) indicate changes in enzyme activity compared to control. 
Comparison was performed by t-test analysis; *P < 0.05, **P < 0.01, ***P < 0.001, 
different from control. 
Figure 7. DNA adduct formation ex vivo by AAI in rat cytosols (A, B) and microsomes (C, D) 
isolated from untreated (control) animals and animals pretreated orally with dicoumarol 
(total doses of 60 [DC60] or 120 mg [DC120] dicoumarol/kg bw) alone or in combination 
with AAI (single i.p. dose of 20 mg/kg bw). AAI-DNA adduct formation was determined 
by 32P-postlabeling in hepatic (A, C) and renal (B, D) fractions. Values are given as the 
means ± SD (n = 3); each DNA sample was determined by two postlabeling analyses. 
RAL, relative adduct labeling. Numbers above columns (“F”) indicate fold changes in 
DNA adduct levels compared to control. Comparison was performed by t-test analysis; 
*P < 0.05, **P < 0.01, ***P < 0.001, different from control.  
Figure 8. CYP2C11 (A) and 2C6 enzyme activities (B) in rat hepatic microsomes isolated 
from untreated (control) animals and animals pretreated orally with dicoumarol (total 
doses of 60 [DC60] or 120 mg [DC120] dicoumarol/kg bw) alone or in combination with 
AAI (single i.p. dose of 20 mg/kg bw). CYP2C11 was measured as testosterone 16α-
hydroxylation (nanomoles 16α-hydroxytestosterone per minute per milligram protein) 
and CYP2C6 as diclofenac 4’-hydroxylation (nanomoles 4’-hydroxydiclofenac per 
minute per milligram protein). All values are given as the means ± SD (n = 3). ##. Sample 
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lost. Numbers above columns (“F”) indicate fold changes in enzyme activities compared 
to control. Comparison was performed by t-test analysis; *P < 0.05, **P < 0.01, ***P < 
0.001, different from control. 
Figure 9. Schematic summary showing the effects of dicoumarol treatment in rats on AAI 
metabolism. NQO1 induction with dicoumarol prior to AAI administration led to 
increased AAI-DNA adduct formation catalyzed by rat hepatic and renal cytosols (see 
panel showing AAI-DNA adduct levels in vitro). Inhibition of CYP2C by dicoumarol 
treatment led to a decrease of AAIa formation in hepatic microsomes (see panel showing 
AAI oxidation in vitro). Both NQO1 induction and CYP2C inhibition increase AAI-DNA 
adduct formation in liver, while only NQO1 induction impacts on AAI-DNA binding in 
kidney (see panels showing AAI-DNA adduct levels in vivo). “F” indicates fold increase 
in rats pretreated with dicoumarol compared to animals treated with AAI alone. 
Comparison was performed by t-test analysis; **P < 0.01, ***P < 0.001. AAI - 
aristolochic acid I; DC – dicoumarol; CYP – cytochrome P450; NQO1 – 
NAD(P)H:quinone oxidoreductase 1.  
 32
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

aristolochic acid I (AAI)
N-hydroxy-
aristolactam I
aristolactam I (AlacI)aristolactam I-
nitreniumion
O
O
COOH
NO2
OCH3
O
O
OCH3
N
O
O
O
OCH3
NH
O
O
O
OCH3
N
O
OH
NH
N
N
O
N
H
N
O
HOH
HH
HH
HO
O
O
H3CO
C
HN
O
dG-AAI NH
NN
N
N
O
HOH
HH
HH
HO
H3CO
O
O
HN
OdA-AAI
O
O
COOH
NO2
OH
aristolochic acid Ia (AAIa)
NR
(e.g. NQO1)
NR
CYP
UGT
SULT
UGT
SULT
AAIa-glucuronide
AAIa-sulfate
AlacI-glucuronide
AlacI-sulfate
 33
 
 
Figure 2 
  
 34
 
 
Figure 3 
  
 35
 
Figure 4 
  
 36
 
Figure 5 
0
1
2
3
4
4
5
6
7
8
9
10
11
1
Pe
a
k 
a
re
a
 
o
f A
A
Ia
A
Pe
a
k 
a
re
a
 
o
f A
A
Ia
B
0
1
2
3
4
5
5
10
15
20
25
30
35
40
45
1
ER
O
D
 
a
c
tiv
ity
C
0
1
2
3
4
5
5
10
15
20
25
30
35
40
45
1
ER
O
D
 
a
c
tiv
ity
D
0
1
2
3
4
5
5
10
15
20
25
30
35
40
45
1
M
R
O
D
 
a
c
tiv
ity
E
0
1
2
3
4
5
5
10
15
20
25
30
35
40
45
1
ND ND ND ND
M
R
O
D
 
a
c
tiv
ity
F
Su
da
n
 
I o
x
id
a
tio
n
G
Su
da
n
 
I o
x
id
a
tio
n
H
Liver Kidney
 37
 
Figure 6 
  
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1
PO
R
 
a
c
tiv
ity
A
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1
PO
R
 
a
c
tiv
ity
BLiver Kidney
 38
 
 
Figure 7 
  
1
0
1
2
3
4
5
6
7
8
1
Cytosol
To
ta
l R
A
L 
pe
r 1
08
n
u
c
le
o
tid
e
s Cytosol
To
ta
l R
A
L 
pe
r 1
08
n
u
c
le
o
tid
e
s
0
1
2
3
4
5
6
7
8
1
To
ta
l R
A
L 
pe
r 1
08
n
u
c
le
o
tid
e
s Microsomes
A
C
B
0
1
2
3
4
5
6
7
8
1
Microsomes
To
ta
l R
A
L 
pe
r 1
08
n
u
c
le
o
tid
e
s
D
Liver Kidney
 39
 
Figure 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CY
P2
C1
1 a
c
tiv
ity
A
CY
P2
C6
 
a
c
tiv
ity
B
0
1
2
3
4
5
6
1
## ##0
1
2
3
4
5
6
1
 40
Exposure to AAI Exposure to DC+AAI
CYP2C
NQO1
CYP2C inhibition
by AAI+DC
NQ
O1
 
ind
uc
tio
n
NQO1 induction 
by  AAI+DC
CYP2C inhibition 
by AAI+DC
NQO1
NQO1 induction 
by  AAI+DC
F=1.4**
F=0.4***
F=1.4**
F=5
.4**
*
F=1
1.0*
**
CYP1A1 CYP1A1
NQ
O1
 
ind
uc
tio
n
 
Figure 9 
